Lukas Hainz

Lukas Hainz

Biopharma Innovation Specialist
Lukas Hainz specializes in biopharmaceutical research and development. He unpacks research from clinical trials and explores regulatory affairs implications on the pharmaceutical industry, focusing on innovative therapies and patent development.
Dampening pDCs Restores T Cells and Shrinks HIV Reservoirs
Biotech & Bioprocessing Dampening pDCs Restores T Cells and Shrinks HIV Reservoirs

Chronic HIV infection, even under suppressive antiretroviral therapy, can trap the immune system in a state of simmering alarm that never fully resolves and quietly erodes the fitness of the very T cells needed for durable control of the virus. That conundrum has intensified attention on the small

Ultrasound Is Radiology: How It Works, Safety, and Costs
Tech & Innovation Ultrasound Is Radiology: How It Works, Safety, and Costs

In emergency rooms, prenatal clinics, and primary care offices alike, clinicians reach for ultrasound because it delivers immediate answers without exposing patients to ionizing radiation, yet it still runs through the same radiology workflows that govern X-rays and CT. That dual identity raises a

AstraZeneca's $2B Maryland Expansion Boosts US Biologics
Biotech & Bioprocessing AstraZeneca's $2B Maryland Expansion Boosts US Biologics

In an era where supply chain resilience and access to life-saving therapies dominate healthcare discussions, AstraZeneca's announcement of a $2 billion investment in Maryland facilities has captured significant attention, raising critical questions about domestic production. This ambitious

Can Bayer’s New Blood Thinner Revolutionize Stroke Care?
Research & Development Can Bayer’s New Blood Thinner Revolutionize Stroke Care?

In a world where a stroke strikes someone every 40 seconds, the fear of a second, potentially fatal event looms large for millions of survivors, creating an urgent need for better solutions. Picture a patient, just recovered from an initial stroke, grappling with the uncertainty of whether their

Is Recursion Pharmaceuticals the Next AI Biotech Giant?
Research & Development Is Recursion Pharmaceuticals the Next AI Biotech Giant?

In the rapidly evolving landscape of biotechnology, few companies have captured the imagination of investors and industry watchers quite like Recursion Pharmaceuticals (NASDARXRX). Headquartered in Salt Lake City, Utah, this clinical-stage “TechBio” firm is at the forefront of a paradigm shift,

World’s First Lung Cancer Vaccine Begins Clinical Trials
Research & Development World’s First Lung Cancer Vaccine Begins Clinical Trials

In a remarkable advancement that could alter the landscape of cancer care, researchers from University College London (UCL) and the University of Oxford have developed LungVax, the world’s first experimental vaccine aimed at preventing lung cancer. This pioneering initiative, now entering clinical

Can Rare Mutations Predict Colorectal Cancer Treatment Success?
Research & Development Can Rare Mutations Predict Colorectal Cancer Treatment Success?

Imagine a scenario where a patient diagnosed with metastatic colorectal cancer (CRC) receives a treatment that not only halts the disease's progression but also leads to remarkable tumor shrinkage, offering a renewed chance at life. This isn’t just a hopeful vision but a reality for a small subset

Machine Learning Tool Optimizes ICU Care for Pneumonia Patients
Tech & Innovation Machine Learning Tool Optimizes ICU Care for Pneumonia Patients

In the high-stakes world of intensive care units (ICUs), severe community-acquired pneumonia (CAP) stands as a formidable adversary, often demanding prolonged hospital stays and extensive resources like ventilatory support, especially among older adults. This condition, contracted outside hospital

In Vivo CAR Cell Therapy: Revolutionizing Immunotherapy
Research & Development In Vivo CAR Cell Therapy: Revolutionizing Immunotherapy

Imagine a world where life-saving cancer treatments no longer require weeks of waiting for cell processing or come with a price tag in the hundreds of thousands of dollars, but instead can be administered in days at a fraction of the cost. This is the promise of in vivo CAR cell therapy, an

AI-Driven Drug Discovery Targets Aging and Alzheimer’s
Tech & Innovation AI-Driven Drug Discovery Targets Aging and Alzheimer’s

In a world where the global population is aging at an unprecedented rate, with projections estimating that nearly a quarter of humanity will be over 65 within the next two decades, the urgency to address age-related diseases like Alzheimer’s has never been more critical, posing immense challenges

Loading
Latest Articles

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later